<DOC>
	<DOCNO>NCT00004252</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . SU5416 may stop growth colorectal cancer stop blood flow tumor . It yet know whether chemotherapy effective without SU5416 treat metastatic colorectal cancer . PURPOSE : Randomized phase III trial compare effectiveness leucovorin fluorouracil without SU5416 treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Leucovorin Fluorouracil With Without SU5416 Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare median survival patient metastatic colorectal cancer treat fluorouracil leucovorin calcium without SU5416 . II . Compare time progression , duration response , objective response patient two regimen . III . Compare percentage 6 month , 9 month , one year survival patient two regimen . IV . Compare time treatment failure patient two regimen . V. Determine health relate quality life patient two regimen . VI . Compare palliative biologic effect SU5416 patient . VII . Determine safety tolerability fluorouracil leucovorin calcium plus SU5416 patient . OUTLINE : This randomize , open label , multicenter study . Patients stratify accord performance status ( ECOG 0 v 1 ) , site primary disease ( colon v rectum ) , measurable evaluable disease , prior fluorouracil adjuvant chemotherapy ( none v least 1 dose ) . Patients randomize one two treatment arm : Arm I : Patients receive leucovorin calcium IV 2 hour fluorouracil IV bolus 1 hour leucovorin calcium administration weekly 6 week . Arm II : Patients receive leucovorin calcium IV 2 hour fluorouracil IV bolus 1 hour leucovorin calcium administration weekly 6 week , plus SU5416 twice weekly 8 week . Treatment repeat every 8 week absence disease progression unacceptable toxicity . Quality life assess prior study , week 4 8 course , post study . Patients follow post study one month every 2 month death . PROJECTED ACCRUAL : A total 710 patient ( 355 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , newly diagnose recurrent , metastatic colorectal cancer Primary disease adenocarcinoma colon rectum Bidimensionally measurable evaluable disease No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 75,000/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin great 2.2 mg/dL AST great 5 time upper limit normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 50 mL/min Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No known allergy Cremophor Cremophor base drug product No uncontrolled colon small bowel disorder No malignancy within past 5 year , except : Basal cell skin cancer Carcinoma situ cervix No acute chronic medical psychiatric condition , laboratory abnormality would preclude compliance PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy , vaccine therapy , cytokine therapy , biologic therapy metastatic disease No prior angiogenesis inhibition therapy ( e.g. , metalloproteinase inhibitor , thalidomide , antiVEGF/Flk1 monoclonal antibody therapy experimental drug act directly VEGF/Flk1 signal pathway ) Prior antibody therapy , immunotherapy , gene therapy , vaccine therapy , cytokine therapy , radioimmunotherapy allow adjuvant set Concurrent epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) allow anemia , neutropenia , thrombocytopenia No concurrent immunotherapy Chemotherapy : No prior systemic chemotherapy metastatic disease No prior intraarterial cytotoxic chemotherapy No one prior course fluorouracil base adjuvant therapy ( e.g. , intravenous fluorouracil capecitabine ) last dose administer least 6 month ago No prior SU5416 No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior radiotherapy Concurrent localize palliative radiotherapy allow unless indicative disease progression Surgery : At least 4 week since prior major surgery ( include surgical placement venous access device ) Prior surgical resection hepatic metastasis allow Other : No prior investigational therapy metastatic disease No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
</DOC>